The Geographic Atrophy Treatment Market is seeing steady expansion as healthcare providers focus on better treatment options for progressive retinal disease. WiseGuyReports estimates the market at USD 2 billion in 2025, with revenue expected to reach USD 5 billion by 2035 at a 6.6% CAGR.

Innovation is being driven by advances in drug development, clinical research, and targeted therapies. Digital health and improved ocular imaging are also becoming more relevant for monitoring patients and supporting research into new treatment approaches.

Surgical therapy held a major position in the treatment landscape, with a market value of USD 720 million in 2024 and a projected value of USD 1.36 billion by 2035. Pharmacological and photocoagulation therapies also contribute to the broader treatment portfolio.

Intravitreal injection is gaining traction because of its targeted delivery capabilities, while oral and topical administration offer additional choices. Hospitals, specialty clinics, and research institutions serve as key end users, with North America maintaining the largest regional presence.

The market has further potential through gene-based therapies, combination treatment strategies, AI-supported monitoring, and wider screening programs. Asia-Pacific may also create new opportunities as healthcare infrastructure and access to geographic atrophy treatments continue to improve.